Related Experiment Video
Updated: Feb 9, 2026
07:49
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
2.0K
NSAIDs and heart failure: A dangerous relationship
Raffaele Rotunno1, Igino Oppo, Gabriele Saetta
1Roccadaspide Hospital, Cardiology Department. raffaele.rotunno@cheapnet.it.
Summary
Anti-inflammatory drugs like NSAIDs and Coxibs can cause heart failure (HF) by affecting fluid balance and blood pressure. Their cardiovascular toxicity, particularly concerning HF, involves renal prostaglandins and differs from their vascular thrombosis risks.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Nephrology
Background:
- Anti-inflammatory drugs, including nonsteroidal anti-inflammatory drugs (NSAIDs) and Coxibs (COX-1 and COX-2 inhibitors), are associated with an increased risk of heart failure (HF) hospitalization.
- These drugs can also lead to vascular thrombosis, with risks varying based on their selective inhibition of cyclooxygenase enzymes.
- The mechanisms underlying cardiovascular toxicity leading to HF differ from those causing vascular thrombosis and involve renal prostaglandins.
Purpose of the Study:
- To elucidate the mechanisms of cardiovascular toxicity of anti-inflammatory drugs, focusing on heart failure.
- To differentiate the pathways of cardiotoxicity and vascular thrombosis induced by NSAIDs and Coxibs.
- To investigate the role of renal prostaglandins (PGE2 and prostacyclin) and their synthesis by COX-2 in the cardiotoxic effects.
Main Methods:
- Review of existing literature on the cardiovascular effects of NSAIDs and Coxibs.
- Analysis of the pharmacological actions of cyclooxygenase inhibitors on fluid retention, blood pressure, and renal function.
- Examination of the specific roles of renal prostaglandins (PGE2, prostacyclin) and the renin-angiotensin-aldosterone system (RAAS) in mediating drug toxicity.
Main Results:
- Both NSAIDs and Coxibs approximately double the risk of hospitalization for heart failure.
- Cardiovascular toxicity leading to HF involves renal prostaglandins (PGE2, prostacyclin), primarily synthesized by COX-2.
- Nimesulide's effects on renal microcirculation are independent of intrarenal RAAS activity, while its effect on sodium excretion is RAAS-dependent.
Conclusions:
- The cardiotoxic effects of anti-inflammatory drugs, leading to heart failure, are mediated through distinct pathways involving renal prostaglandins, separate from their vascular thrombosis risks.
- COX-2 inhibition plays a significant role in the cardiotoxicity of these drugs by affecting renal prostaglandins crucial for vasodilation.
- Understanding these mechanisms is vital for managing the cardiovascular risks associated with anti-inflammatory drug use.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
978
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
978
01:17Pathophysiology of Heart Failure
3.9K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.9K
01:27Heart Failure I: Introduction
927
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
927
01:22Heart Failure VI: Adjunct Therapies
368
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
368
01:22Heart Failure Drugs: Diuretics
990
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
990
01:30Heart Failure V: Medical Management
342
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
342